Asia, Israel (Teva?) to steer 'golden era' of regenerative meds
This article was originally published in Scrip
Executive Summary
Industry is probably headed towards the ''golden era'' in regenerative medicine/stemcell-based therapies, with the segment achieving critical mass, and clarity emerging on regulatory pathways and pivotal data readouts anticipated, finds a report by MP Advisors, an Indian strategic business advisory firm.